Immune System

Antibiotic allergy de-labeling and skin testing

Clinical Overview and When to Suspect Mislabeled Antibiotic Allergy

— Higher rates of MRSA, VRE, and C. difficile colonization/infection

— Increased surgical site infections (cefazolin avoidance in perioperative prophylaxis)

— Longer length of stay, higher readmission rates, higher cost

— Suboptimal therapy in syphilis (pregnancy), endocarditis, neurosyphilis, GBS prophylaxis

— Any hospitalized patient on a non–beta-lactam due to listed allergy

— Preoperative clinic visit, especially orthopedic, cardiac, OB

— Pregnancy with syphilis, GBS+, or planned cesarean

— Oncology/transplant patients before neutropenia or prophylaxis decisions

— Recurrent infections requiring repeated antibiotic courses

— Outpatient primary care annual visit—an underused opportunity

— Type A (predictable, non-immune): GI upset, headache, yeast infection — not an allergy; remove the label

— Type B (immunologic): IgE-mediated (urticaria, anaphylaxis, <1–6 h), T-cell mediated (delayed maculopapular rash, days), severe cutaneous adverse reactions (SCARs: SJS/TEN, DRESS, AGEP)

The problem: ~10% of US patients carry a "penicillin allergy" label, but >95% can tolerate penicillins on formal evaluation. Mislabeling drives use of broader, costlier, more toxic alternatives (vancomycin, fluoroquinolones, clindamycin, aztreonam) with measurable harm.

Documented harms of an unverified PCN allergy label:

When to actively pursue de-labeling:

Allergy label categories to clarify before action:

Step 3 management: A careful history alone safely de-labels ~30–50% of "penicillin-allergic" patients — those with intolerance, vague childhood rash >10 years ago without features of anaphylaxis, or family-history-only labels. No skin testing required for these.

Board pearl: The PEN-FAST score (5 points: ≤5 yrs ago=2, Anaphylaxis/angioedema OR Severe cutaneous reaction=2, Treatment required=1) stratifies risk; score 0 = <1% positive skin test, candidate for direct oral amoxicillin challenge.

Presentation Patterns and Key History

— What drug (and class — was it really penicillin, or amoxicillin-clavulanate where clavulanate caused the reaction?)

— When did it occur (years ago vs. recent; childhood reactions often viral exanthems mislabeled)

— What reaction (hives, swelling, breathing difficulty, anaphylaxis, blistering, mucosal involvement, organ dysfunction)

— Timing from dose to symptoms (<1 h suggests IgE; 1–6 h still possible IgE; >6 h–days suggests T-cell delayed; weeks suggests DRESS or serum sickness–like)

— Treatment required (none, antihistamine at home, ED visit, epinephrine, ICU)

— Tolerance since of related agents (cephalosporins, amoxicillin in dental work) — tolerance is reassuring

— Isolated GI symptoms, headache, vaginal candidiasis

— Family history only, or "mother said I'm allergic"

— Remote (>10 yr) mild rash without urticaria, hypotension, mucosal or systemic features

— Subsequent uneventful exposure to a related beta-lactam

— Urticaria, angioedema, wheezing, hypotension within minutes–hours

— Required epinephrine, ED visit, or hospitalization

— Reaction during or shortly after IV dose

— SCARs: SJS/TEN, DRESS/DIHS, AGEP, acute interstitial nephritis, drug-induced hepatitis, hemolytic anemia, serum sickness with arthritis/nephritis

— These patients should never undergo skin testing or challenge — proceed to alternative class

The de-labeling history is the single highest-yield exam tool. Cover six domains systematically:

Reassuring history (consider direct oral challenge):

History suggesting true IgE allergy (skin test first):

History excluding any future beta-lactam rechallenge (absolute contraindication):

Key distinction: "Amoxicillin rash in a child during mono/viral illness" is the classic delayed maculopapular eruption — non-IgE, non-recurrent, and does not preclude future penicillin use; this is a high-yield de-labeling scenario on Step 3.

Board pearl: Always document the reaction phenotype in the chart, not just "PCN allergy" — phenotype determines whether testing, challenge, or strict avoidance is correct.

Physical Exam Findings and Hemodynamic Assessment

— Skin: urticaria, flushing, angioedema (lips, tongue, periorbital)

— Airway: stridor, hoarseness, tongue swelling

— Lungs: wheezing, accessory muscle use

— CV: tachycardia, hypotension, syncope (distributive shock)

— GI: cramping, vomiting, diarrhea

— Two-system involvement after suspected allergen = anaphylaxis, treat immediately with IM epinephrine 0.3–0.5 mg lateral thigh

— SJS/TEN signs: mucosal erosions (oral, conjunctival, genital), Nikolsky sign, dusky targetoid lesions, skin pain out of proportion, fever

— DRESS: facial edema, diffuse morbilliform rash >50% BSA, lymphadenopathy, fever, eosinophilia, hepatitis

— AGEP: sterile non-follicular pustules on erythematous base, fever, neutrophilia

— SJS/TEN, DRESS, AGEP → permanent avoidance of class

— Vital signs stable; no active urticaria, asthma exacerbation, or febrile illness

— Skin clear at planned testing sites (volar forearm, back)

— No beta-blocker or ACEi if avoidable (blunts epinephrine response, worsens anaphylaxis)

— No antihistamines for 3–7 days (false negatives) — but DO NOT stop the drug if needed for symptoms; defer testing instead

In the de-labeling encounter itself, exam is usually normal — the historical reaction is the data. Exam matters in two scenarios: (1) evaluating a current/recent drug reaction, and (2) monitoring during in-office challenge or graded administration.

Acute IgE/anaphylactic reaction exam (must recognize during testing):

Delayed/T-cell reaction exam clues that argue against challenge:

Pre-testing exam checklist (skin testing or oral challenge):

CCS pearl: During an in-office oral amoxicillin challenge, order vital signs q15min × 1 h after dose, have IM epinephrine, IV access capability, oxygen, and an observation period of at least 60 minutes before discharge.

Step 3 management: Any hypotension or two-system reaction during challenge → epinephrine IM first, then IV fluids, H1/H2 blockers, steroids as adjuncts (not substitutes for epi).

Diagnostic Workup — Initial Risk Stratification and PEN-FAST

— (a) Not an allergy (intolerance, GI, family hx) → de-label by history alone

— (b) Low-risk allergy (remote, mild, no anaphylaxis features) → direct oral challenge

— (c) Moderate/high-risk IgE features (anaphylaxis, urticaria <6 h, ED visit) → skin testing first

— (d) Delayed mild rash (benign maculopapular, no SCAR features) → delayed challenge or graded dose

— (e) SCAR or organ-specific reaction → strict avoidance, no testing

— Penicillin allergy reported

— Five years or less since reaction: 2 points

— Anaphylaxis/angioedema OR Severe cutaneous reaction: 2 points

— Treatment required for reaction: 1 point

— Score 0: very low risk (<1%) → direct oral amoxicillin challenge appropriate

— Score 1–2: low risk (~5%) → consider skin testing or supervised challenge

— Score 3: moderate (~20%) → skin testing first

— Score ≥4: high (~50%) → skin testing, consider allergy referral

— CBC with differential if prior DRESS suspicion (eosinophilia, atypical lymphocytes)

— LFTs, creatinine if prior organ involvement reported

— Tryptase (baseline) if mastocytosis suspected or recurrent unexplained anaphylaxis

— Serum IgE panels to penicillin are not recommended as primary screen — low sensitivity (~50%), high false-negative rate; positives still require confirmation

— Routine total IgE has no role

De-labeling diagnostics are largely clinical and structured; "labs" are mostly tools to stratify who needs what test.

Step 1 — Phenotype the reaction (history): Sort into one of five buckets:

Step 2 — Apply PEN-FAST (validated for penicillin):

Baseline labs — limited role:

What NOT to order:

Board pearl: PEN-FAST 0 has a negative predictive value >99% for true penicillin allergy — direct oral challenge with 250–500 mg amoxicillin and 1-hour observation is now standard of care in many US health systems, including primary care settings.

Key distinction: Specific IgE serology is adjunctive only; a negative result does not exclude allergy and a positive does not confirm clinical reactivity.

Diagnostic Workup — Skin Testing and Graded Challenge

— Major determinant: benzylpenicilloyl polylysine (PrePen, PPL) — accounts for ~85% of IgE responses

— Minor determinants: benzylpenicillin (Pen G) 10,000 U/mL ± minor determinant mixture (limited US availability)

— Positive and negative controls: histamine and saline

— Step 1 — Epicutaneous (prick): drop on volar forearm, lancet prick; read at 15 min; wheal ≥3 mm larger than saline control with erythema = positive

— Step 2 — Intradermal (only if prick negative): 0.02 mL intradermal on upper arm; read at 15 min; wheal ≥3 mm increase = positive

— Step 3 — If both negative → oral amoxicillin challenge: 250–500 mg PO, observe 1 hour; if no reaction → de-labeled

— Non-irritating concentrations established for cefazolin, ceftriaxone, cefepime, meropenem

— Cross-reactivity between PCN and cephalosporins is <2%, driven by R1 side-chain similarity (e.g., amoxicillin ↔ cefadroxil, cefprozil; ampicillin ↔ cephalexin, cefaclor)

— Cefazolin has a unique side chain — safe in most PCN-allergic patients

Penicillin skin testing (PST) is the gold standard for IgE-mediated penicillin allergy with a negative predictive value ~97–99% when combined with oral amoxicillin challenge.

Reagents (US):

Procedure:

Cephalosporin and other beta-lactam testing:

Aztreonam: no cross-reactivity with penicillins/cephalosporins except ceftazidime (shared side chain) — safe alternative

Carbapenems: cross-reactivity <1% — generally safe with caution

Graded challenge (alternative when testing unavailable): 1/100, then 1/10, then full dose at 30-min intervals; appropriate for low-to-moderate risk.

Step 3 management: Order PCN skin test → oral amoxicillin challenge sequence in any inpatient on a non–beta-lactam for an infection where a beta-lactam would be first-line (e.g., MSSA bacteremia needing cefazolin, syphilis in pregnancy).

CCS pearl: In CCS-style cases, "consult allergy/immunology" is the right move for skin testing if the local setting allows; otherwise low-risk patients can have primary-team-supervised oral challenge.

Risk Stratification and Management Algorithm

— Isolated non-allergic symptoms (GI, headache, yeast)

— Family history only

— Unknown reaction >10 years ago without anaphylaxis features

— Benign childhood maculopapular rash (often during viral illness)

— PEN-FAST score 0–1

— Subsequent tolerance of a related beta-lactam

— Action: 250–500 mg amoxicillin PO, observe 1 hour, then 5-day course or single observed dose depending on protocol; update chart immediately

— Urticaria or angioedema >10 years ago without anaphylaxis

— Reaction with unclear features

— PEN-FAST 2–3

— Action: Refer to allergy or use inpatient antimicrobial stewardship pathway; PST → if negative, oral challenge

— Anaphylaxis, especially recent (<5 years)

— Required epinephrine or ICU care

— PEN-FAST ≥4

— Action: Formal allergy evaluation; if drug truly required and no alternative, desensitization under monitored setting

— SJS/TEN, DRESS, AGEP

— Drug-induced hemolytic anemia, AIN, hepatitis, serum sickness

— Class-wide avoidance documented; use structurally unrelated alternatives

— Phenotype reaction → if non-allergic or low risk: use beta-lactam (often cefazolin or amoxicillin)

— If moderate risk and beta-lactam strongly preferred: skin test → challenge

— If high risk and beta-lactam essential (syphilis in pregnancy, neurosyphilis, enterococcal endocarditis): desensitization

— If SCAR history: alternative class

Three-tier risk stratification drives every decision:

Low risk (proceed to direct oral challenge, no skin test needed):

Moderate risk (skin testing recommended before challenge):

High risk (allergy specialist; consider desensitization if drug essential):

Absolute avoidance (NEVER test or challenge):

Step 3 management algorithm — penicillin-labeled patient needing antibiotic now:

Board pearl: Cefazolin should be used for surgical prophylaxis in patients with a PCN allergy label unless they have a documented severe IgE or SCAR reaction — switching to vancomycin doubles SSI risk.

Pharmacotherapy — Desensitization and Premedication Protocols

— Patient has true IgE-mediated allergy AND

— The specific drug is clearly superior with no acceptable alternative

— Classic indications: syphilis in pregnancy (penicillin is the only proven treatment), neurosyphilis, enterococcal endocarditis, listeria meningitis, treponemal disease, certain CF/Pseudomonas regimens

— Starting dose ~0.05 mg, doubling every 15 minutes over ~4 hours to therapeutic dose (~14 steps)

— IV protocol available for NPO patients or critical illness

— Performed in monitored setting (ICU or step-down) with IV access, epinephrine, antihistamines, steroids at bedside

— Continuous therapy required — a missed dose = loss of tolerance, must redesensitize

— Prior SJS/TEN, DRESS, AGEP, hemolytic anemia, AIN, hepatitis, serum sickness — desensitization does not protect against T-cell or non-IgE reactions

— Severe cardiopulmonary instability that would not tolerate anaphylaxis

— Diphenhydramine + acetaminophen 30–60 min pre-infusion, slow infusion rate (over ≥2 h)

— Not appropriate for true IgE allergy — premedication does NOT prevent anaphylaxis

— First-line for anaphylaxis: IM epinephrine 0.3–0.5 mg (1:1000) lateral thigh, repeat q5–15 min

— IV fluids (1–2 L NS bolus) for hypotension

— H1 (diphenhydramine 25–50 mg IV) + H2 (famotidine 20 mg IV) — adjuncts only

— Methylprednisolone 1–2 mg/kg IV to prevent biphasic reaction

— Albuterol for bronchospasm

— Glucagon 1–5 mg IV if on beta-blocker and refractory hypotension

Drug desensitization induces temporary tolerance by gradual dose escalation, lost ~24–48 hours after last dose. Used when:

Penicillin desensitization protocol (oral, preferred when possible):

Contraindications to desensitization:

Premedication for non-IgE reactions (e.g., vancomycin infusion reaction/"red man"):

Adjunct drugs during testing/challenge reactions:

CCS pearl: Order "desensitization protocol, allergy consult, ICU bed, epinephrine at bedside, continuous telemetry" as a bundle in CCS cases of pregnant syphilis patients with documented PCN anaphylaxis.

Board pearl: Desensitization tolerance is dose-specific and time-limited — it must be repeated for each treatment course.

Procedures — Performing the Oral Amoxicillin Challenge

— Low-risk history by PEN-FAST or equivalent

— No SCAR features ever

— No active uncontrolled asthma, unstable angina, or pregnancy in some protocols (though pregnancy with syphilis is itself an indication)

— Able to remain for observation

— Not on beta-blocker if avoidable

— Resuscitation-capable space (IM epi, oxygen, IV supplies, BP cuff)

— Trained staff present for ≥1 hour post-dose

— Documented protocol and consent

— Baseline vitals, brief exam (skin, lungs)

— Administer amoxicillin 250 mg PO (some protocols 500 mg)

— Vital signs and symptom check q15 min × 4

— Observe minimum 60 min after dose

— If no reaction → de-labeled; document in EHR allergy section, communicate to patient and pharmacy

— 1/10 dose (25–50 mg), wait 30 min

— Then full 250 mg, observe 60 min

— Observed first dose in clinic

— Patient continues amoxicillin 500 mg TID × 5 days at home

— Patient instructed to stop and call if rash, fever, mucosal symptoms

— Captures delayed T-cell reactions missed by single-dose

— Update structured allergy field in EHR (delete or annotate "tolerated amoxicillin challenge [date]")

— Notify primary care, surgery teams, pharmacy

— Provide patient written documentation/card

— Educate that label removal applies to penicillin class, not all antibiotics

The direct oral amoxicillin challenge is now the most impactful de-labeling procedure in general medicine and can be performed by trained internists, hospitalists, and increasingly primary care.

Patient selection (must meet ALL):

Setting requirements:

Procedure — single-dose protocol (most common):

Procedure — two-step graded challenge (for slightly higher-risk or cautious settings):

Five-day extended challenge (used for delayed-reaction concerns):

Post-challenge documentation (critical and often missed):

Step 3 management: Failure to update the EHR allergy field after successful challenge is the most common de-labeling failure mode — the label re-propagates across encounters and undoes the work.

CCS pearl: "Update allergy list" is an explicit order in CCS cases after challenge; without it, you lose credit for the intervention.

Special Populations — Elderly and Renal/Hepatic Impairment

— More frequent hospitalizations, surgeries, and antibiotic courses

— Higher rates of C. difficile from broad alternatives (clindamycin, fluoroquinolones)

— Fluoroquinolone risks magnified: tendinopathy, QT prolongation, delirium, hypoglycemia (especially with sulfonylureas), aortic aneurysm/dissection

— Vancomycin nephrotoxicity risk increased with age and polypharmacy

— De-labeling has the highest absolute benefit in this group

— Reactions reported are often >40 years old — frequently mislabeled viral exanthems or unrelated symptoms

— Cognitive impairment may limit history reliability — corroborate with family, old records

— Polypharmacy: review for beta-blockers (relative caution; do not stop chronically but have glucagon ready), ACEi (increased angioedema risk during challenge), antihistamines (hold 3–7 days)

— Lower threshold for graded challenge over direct single-dose

— Does not change de-labeling decisions but affects subsequent antibiotic dosing

— Amoxicillin 250 mg challenge dose is safe across CKD stages (no dose adjustment needed for a single test dose)

— If full course follows, adjust amoxicillin for CrCl <30 (250 mg q12h or q24h)

— Cefazolin, cephalexin, piperacillin-tazobactam all require renal dose adjustment — relevant once de-labeled

— Amoxicillin/penicillin minimally hepatically cleared — safe for challenge

— Caution with amoxicillin-clavulanate post de-labeling: clavulanate-associated cholestatic hepatitis risk, especially older men, prolonged courses

— Document that the prior reaction may have been to clavulanate, not amoxicillin — testing/challenging with plain amoxicillin is preferred

Older adults (>65) carry disproportionate burden of PCN allergy labels (often >15%) and disproportionate harm:

Considerations specific to elderly de-labeling:

Renal impairment:

Hepatic impairment:

Key distinction: A reaction to amoxicillin-clavulanate is not equivalent to a penicillin allergy; ~30% of such reactions are to clavulanate alone. Plain amoxicillin challenge is often successful.

Board pearl: In a nursing home resident with recurrent UTIs on ciprofloxacin and a 50-year-old "PCN allergy," outpatient de-labeling with PEN-FAST + oral amoxicillin challenge is a high-value Step 3 ambulatory intervention.

Special Populations — Pregnancy, Pediatrics, Immunocompromised

— Syphilis in pregnancy: penicillin is the only treatment proven to prevent congenital syphilis; alternatives (doxycycline contraindicated, azithromycin resistance, ceftriaxone limited data) are inadequate

— Group B Strep prophylaxis: PCN/ampicillin first-line; cefazolin acceptable if low-risk PCN allergy; clindamycin only if susceptibility confirmed AND high-risk allergy; vancomycin reserved for clindamycin-resistant GBS with severe allergy

— Cesarean prophylaxis: cefazolin standard; vancomycin substitution increases SSI

— Approach: Skin testing is safe in pregnancy and recommended in 2nd–3rd trimester when allergy is high-risk; low-risk patients can undergo oral challenge antepartum

— If true PCN allergy + syphilis: desensitize and treat with penicillin

— "Amoxicillin rash" during childhood otitis or strep is the prototypical mislabeled reaction — most are viral exanthems or non-IgE benign maculopapular rashes

— Direct oral amoxicillin challenge is safe and increasingly performed in pediatric outpatient settings for low-risk children

— Carries forward lifelong benefit; de-label early

— PEN-FAST validated mostly in adults; pediatric tools include the PIPA score

— De-label before transplant or chemotherapy when feasible

— Allows cefazolin/cefepime/piperacillin-tazobactam for febrile neutropenia rather than meropenem or aztreonam + vancomycin

— Reduces breakthrough resistant infections and C. difficile in this fragile group

— Higher rates of drug hypersensitivity in general (sulfonamides especially)

— Abacavir hypersensitivity tied to HLA-B*57:01 — mandatory pretesting before initiation; positive = absolute contraindication

— Same de-labeling principles apply for beta-lactams

Pregnancy — highest-stakes scenario for de-labeling:

Pediatrics:

Immunocompromised / transplant / oncology:

HIV:

Step 3 management: A pregnant woman with positive syphilis serology and a remote "rash on penicillin as a child" gets a same-day allergy consult; if high-risk by history → skin test, if negative → treat with penicillin; if positive or unable to test → desensitize and treat. Never substitute an inferior agent.

Board pearl: HLA-B*15:02 screening before carbamazepine in Asian patients prevents SJS/TEN — analogous pharmacogenomic de-risking principle.

Complications and Adverse Outcomes

— Increased mortality in MSSA bacteremia treated with vancomycin vs. cefazolin

— Higher SSI rates after orthopedic, cardiac, and OB surgery

— Increased C. difficile infection (clindamycin, fluoroquinolones, broad cephalosporins)

— MRSA and VRE acquisition

— Treatment failure in syphilis, endocarditis, neurosyphilis, listeria

— Longer hospitalization, higher 30-day readmissions

— Higher direct drug costs (vancomycin levels, infusion time, line complications)

— Anaphylaxis during skin testing or challenge: ~1–3% in moderate-risk, <1% in low-risk; managed with IM epinephrine

— Delayed maculopapular rash after extended challenge: usually benign, self-limited, label updated to "delayed rash, non-severe"

— Vasovagal reaction during skin testing — distinguish from anaphylaxis (bradycardia + pallor vs. tachycardia + flushing)

— False de-labeling: extremely rare with proper protocols; multi-step challenge reduces this

— Mild reactions during escalation (urticaria, pruritus, transient hypotension) in ~30% — treated with antihistamines, slow rate, complete protocol

— Severe anaphylaxis <1% with appropriate selection

— Loss of tolerance if dose interrupted >24–48 h → must redesensitize before continuing

— Anxiety about losing a "safety net" diagnosis — counsel that de-labeling is liberating, not dangerous

— Reintroduction of the label by patients themselves at future encounters — provide written documentation

— Label re-propagation across EHRs when records are imported from outside systems — flag for review

— Inconsistent documentation between problem list, allergy list, and clinical note

Complications of leaving the allergy label in place (the "cost of inaction"):

Complications of the de-labeling intervention itself (uncommon but must anticipate):

Complications of desensitization:

Patient psychological complications:

Health systems–level complications:

CCS pearl: Post-challenge, document de-labeling in three places: EHR allergy module, discharge summary, and patient handout. Missing any one allows re-labeling.

Board pearl: The largest mortality difference attributable to a PCN allergy label is in MSSA bacteremia — cefazolin/nafcillin outperforms vancomycin; this is a frequent Step 3 stem.

When to Escalate Care — Allergy Consult, ICU, and Setting

— High-risk history (anaphylaxis, especially recent)

— Multiple drug allergies or "multiple antibiotic allergy syndrome"

— Reaction features uncertain or mixed (immediate + delayed)

— Patient with prior failed challenge or recurrent reactions

— Need for desensitization

— Suspected mastocytosis or elevated baseline tryptase

— Pediatric high-risk reactions

— Hospitalized patient on a suboptimal antibiotic due to label

— Pre-surgical patient with label and planned cefazolin prophylaxis

— Patient receiving vancomycin for MSSA bacteremia

— Many academic centers have proactive PCN allergy de-labeling teams — order early in admission

— Outpatient primary care or allergy clinic: low-risk, PEN-FAST 0–1, direct oral challenge

— Inpatient ward with monitoring: moderate risk, skin test + challenge, ASP-supervised

— ICU or step-down: desensitization, high-risk reactions, unstable patient who needs the drug now

— Anaphylaxis with hypotension unresponsive to first epinephrine dose

— Airway compromise requiring intubation

— Need for epinephrine drip

— Biphasic reaction risk (severe initial reaction) — observe 4–6 h or admit

— Patient labeled PCN-allergic going to OR for cardiac, orthopedic, or major abdominal surgery → de-label in preoperative clinic ≥2 weeks before surgery when possible

— Emergent surgery with PCN label → use cefazolin if no SCAR/anaphylaxis history (still safer than vancomycin)

Escalate to allergy/immunology specialist when:

Inpatient antimicrobial stewardship / pharmacy consult when:

Setting selection for testing/challenge:

ICU escalation triggers during testing/challenge:

Pre-procedural escalation:

Step 3 management: A hospitalized patient with MSSA endocarditis and a remote PCN rash should have infectious disease consult, antimicrobial stewardship/allergy de-labeling pathway initiated within 24 hours, with the goal of switching from vancomycin to cefazolin or nafcillin.

CCS pearl: In CCS, ordering "allergy consult" advances the clock and yields the most accurate testing recommendation; pair with "infectious disease consult" and "pharmacy consult" for full-credit management.

Key Differentials — Reactions That Look Like Allergy But Aren't

— GI upset with macrolides, amoxicillin-clavulanate — predictable, dose-related, not immune

— Headache, dizziness, nausea with various antibiotics — Type A adverse effect

— Vaginal candidiasis after broad-spectrum antibiotics — expected microbiome effect

— Diarrhea including C. difficile — not allergy, but a serious AE; document as such

— Photosensitivity with tetracyclines, fluoroquinolones, sulfonamides — phototoxic, not IgE

— QT prolongation with macrolides, fluoroquinolones — pharmacologic toxicity

— Tendon rupture with fluoroquinolones — toxicity, label appropriately

— Vancomycin infusion reaction ("red man syndrome"): flushing, pruritus, mild hypotension from direct mast cell degranulation; resolves with slower infusion + antihistamine; not an allergy, can rechallenge

— Amphotericin B infusion reaction: rigors, fever — premedicate, not allergy

— Rapid IV ciprofloxacin can cause flushing — pseudoallergic

— NSAID/aspirin urticaria, angioedema, AERD — COX-1 mediated, cross-reacts across NSAIDs but not IgE-specific

— Opioid pruritus and flushing — direct mast cell degranulation; "morphine allergy" is almost always intolerance

— Radiocontrast reactions — mostly non-IgE; premedication regimens exist

— Amoxicillin + EBV/mononucleosis → near-universal morbilliform rash, not a true allergy; patient can later tolerate amoxicillin

— Classic Step 3 stem: teen on amoxicillin for "strep throat" who actually had mono, develops rash, labeled allergic — de-label by history

— Pallor, bradycardia, diaphoresis — not anaphylaxis (which has tachycardia, flushing)

Drug intolerances mislabeled as allergy (same-category mimics):

Non-allergic infusion reactions:

Pseudoallergic reactions:

Viral exanthem mislabeled as drug rash:

Anxiety/vasovagal during injection:

Key distinction: Tachycardia + urticaria + flushing = anaphylaxis. Bradycardia + pallor + diaphoresis = vasovagal. The vital signs differentiate.

Board pearl: "Red man syndrome" is the most commonly mislabeled antibiotic "allergy" on Step 3 — the correct action is slow the infusion and premedicate, not switch to linezolid or daptomycin.

Key Differentials — True Immunologic Reactions to Distinguish

— Drug-induced hemolytic anemia (high-dose penicillin, cephalosporins, ceftriaxone) — positive direct Coombs, anemia, hyperbilirubinemia

— Drug-induced thrombocytopenia (sulfonamides, vancomycin, linezolid)

— Drug-induced neutropenia

— Management: discontinue, supportive; do not rechallenge or desensitize

— Serum sickness / serum sickness–like reaction (cefaclor classic in children, also amoxicillin, sulfonamides, minocycline): 7–14 days post-exposure, fever, urticaria, arthralgias, lymphadenopathy

— Drug-induced lupus (procainamide, hydralazine, minocycline, isoniazid)

— Vasculitis

— Management: discontinue, NSAIDs/steroids; class avoidance often appropriate

— Benign maculopapular exanthem — most common, days into therapy; not dangerous, may permit cautious rechallenge

— Fixed drug eruption — recurrent same-site lesion (sulfonamides, NSAIDs, tetracyclines)

— Contact dermatitis (topical neomycin, bacitracin)

— SCARs (always avoid):

– SJS/TEN: mucosal erosions, epidermal detachment; sulfonamides, allopurinol, anticonvulsants; HLA-B15:02 (carbamazepine, Asians); HLA-B58:01 (allopurinol)

– DRESS/DIHS: 2–8 weeks post-start, fever, rash >50% BSA, eosinophilia, lymphadenopathy, hepatitis/nephritis; aromatic anticonvulsants, sulfonamides, allopurinol, vancomycin (linear gingival), minocycline

– AGEP: rapid pustular eruption, fever, neutrophilia; aminopenicillins, macrolides, diltiazem

— AIN (penicillins, NSAIDs, PPIs, sulfonamides) — fever, rash, eosinophilia, WBC casts

— Cholestatic hepatitis (amoxicillin-clavulanate, macrolides) — class caution

Beyond IgE-mediated immediate hypersensitivity, recognize four other immunologic mechanisms — each demands different management:

Type II (cytotoxic, IgG/IgM-mediated):

Type III (immune complex):

Type IV (T-cell mediated, delayed):

Drug-induced organ-specific reactions:

Step 3 management: SCAR or organ-specific reaction = permanent class avoidance, no testing, no desensitization — these are not IgE phenomena and tolerance cannot be safely induced.

Board pearl: "Vancomycin + linear IgA bullous dermatosis" and "vancomycin + DRESS" are favorite trap questions — neither is reversible by premedication.

Secondary Prevention — Documentation, EHR, and Long-Term Plan

— Remove the "penicillin allergy" entry, OR annotate "tolerated oral amoxicillin challenge [date] — penicillin class not contraindicated"

— Do not simply add a note in narrative — must be in the structured allergy field where decision support pulls from

— Update problem list if "drug allergy" was an active problem

— Send EHR cross-system message if patient has records in affiliated systems

— Provide a wallet card or printed letter stating de-labeling status, date, agent challenged, dose, observation

— Counsel: "If asked about a penicillin allergy in the future, say it was tested and removed on [date]"

— Address anxiety: validated worry about losing the label is common; emphasize benefit

— Notify PCP (with documentation)

— Notify pharmacy of record

— If patient has upcoming surgery, dental procedure, or pregnancy — notify those teams explicitly

— Discharge summary line item: "Penicillin allergy de-labeled — see allergy module"

— Annual reinforcement at primary care visits — verify label remains updated

— If new "allergy" surfaces at later encounter, investigate before accepting the label

— Track outcomes: subsequent beta-lactam use, infections, surgeries

— Successful amoxicillin challenge → all penicillins, cephalosporins, and carbapenems are reasonable (with usual caution for new reactions)

— Skin-test-negative + amoxicillin challenge → essentially full beta-lactam access

— If only cefazolin tested → document scope of clearance accurately

The de-labeling is incomplete until documentation propagates — this is where most real-world programs fail.

EHR allergy module update (the single most important step):

Patient-facing documentation:

Communication to other clinicians:

Long-term plan elements:

Class implications to specify in chart:

Step 3 management: At every transitions-of-care touchpoint (admission, discharge, surgery, pregnancy intake, oncology intake), the allergy list should be reconciled and verified — analogous to medication reconciliation.

Board pearl: "Allergy reconciliation" parallels "medication reconciliation" as a Joint Commission–style patient safety step — failure to do so is a recurring root cause in adverse events on Step 3 quality/safety questions.

Follow-Up, Monitoring, and Counseling

— Observation 60 minutes minimum after dose

— Discharge instructions: return for rash, hives, fever, mouth sores, breathing difficulty, swelling

— Phone follow-up at 24–48 h to capture delayed reactions

— Many programs send a 1-week patient-reported outcome survey

— Patient diary for symptoms

— Stop drug and call for any rash, fever, or systemic symptoms

— Clinical recheck at end of course or telehealth check-in

— Document "tolerated 5-day course" in allergy module

— Continuous telemetry during escalation

— Frequent vitals (q15 min during escalation, q30–60 min during maintenance)

— Monitor for breakthrough reactions throughout treatment course

— Reassess if any dose missed >24 h — likely need redesensitization

— At each primary care visit for 1 year, verify allergy list reflects de-labeled status

— Document any subsequent beta-lactam exposures and tolerability — reinforces removal

— No routine labs needed

— Track quality metrics at the practice level: % of labeled patients evaluated, % de-labeled

— Explain mechanism: "Most childhood penicillin allergies are mislabeled — viral rashes or non-allergic effects."

— Discuss benefits: shorter hospital stays, fewer C. diff infections, better surgical outcomes, broader treatment options

— Acknowledge that new allergic reactions to any drug are always possible — de-labeling does not mean immortality from reactions

— Reassure that desensitization is an option if a true allergy is later confirmed

— Provide written materials

— Pregnant patient: emphasize fetal protection from syphilis or GBS sepsis

— Pre-op patient: explain SSI reduction with cefazolin

— Cancer patient: better neutropenic fever coverage

Immediate post-procedure follow-up (single-dose oral challenge):

Extended (5-day) challenge follow-up:

Post-desensitization monitoring:

Long-term outpatient monitoring after de-labeling:

Patient counseling points:

Counseling in high-stakes scenarios:

CCS pearl: "Patient education" and "schedule follow-up in 2 weeks" are explicit CCS orders that reinforce safety net and capture late reactions.

Board pearl: Telephone or telehealth follow-up at 48–72 hours after challenge is a low-cost, high-value safety measure increasingly mandated by program protocols.

Ethical, Legal, and Patient Safety Considerations

— Document discussion of risks (anaphylaxis ~1%), benefits (improved future antibiotic access, reduced harms), and alternatives (continue label, use alternative antibiotic)

— Pediatric challenges: parental consent + age-appropriate assent

— In pregnancy with syphilis requiring desensitization, explain that failure to treat carries fetal mortality and morbidity exceeding maternal desensitization risk — a classic ethical balancing test

— Patient refuses de-labeling despite low-risk history → respect, document, revisit at future visits; this is not "non-adherence" but a values choice

— Patient demands alternative antibiotic despite negative testing → physician should explain but may comply if no harm; document shared decision

— Pregnant patient refuses desensitization for syphilis → involve ethics, MFM, social work; explore reasoning; cannot force treatment but must counsel re: congenital syphilis consequences

— Most de-labeling failures occur because the label re-enters the EHR at a different facility, urgent care, or after a records import

— Mitigation: structured documentation, patient wallet card, communication to PCP/pharmacy, explicit discharge summary line

— Anaphylaxis during in-office challenge: institutional adverse event report; root cause analysis if severe

— SCAR reactions: report to FDA MedWatch

— Some states require reporting of severe drug reactions

— Minority and low-income patients are less likely to be de-labeled — disparity in access to allergy specialists

— Primary care–based oral challenge programs are an equity intervention

— Document language-concordant counseling, use professional interpreters (not family)

— Withholding standard-of-care antibiotic (e.g., cefazolin for surgery) based on an undocumented "allergy" without attempting clarification is increasingly viewed as substandard care

— Conversely, performing a challenge without informed consent or appropriate monitoring is unsafe practice

Informed consent for skin testing, oral challenge, and desensitization:

Patient autonomy edge cases:

Transitions of care — the dominant safety risk:

Mandatory reporting and adverse event documentation:

Health equity and access:

Liability considerations:

Step 3 management: When a pregnant patient with syphilis refuses penicillin desensitization, the correct response is counsel exhaustively, document, offer ethics consult, treat with best available alternative while continuing to advocate for desensitization — never coerce, never abandon.

Board pearl: The transition-of-care label re-propagation is the prototypical Step 3 patient safety question on this topic.

High-Yield Associations and Rapid-Fire Clinical Facts

— ~10% of US patients labeled PCN-allergic; >95% can tolerate penicillin on testing

— Cross-reactivity between PCN and cephalosporins: <2%; with carbapenems <1%; with aztreonam near 0 (except ceftazidime)

— PEN-FAST score 0 NPV >99% for true PCN allergy

— Amoxicillin ↔ cefadroxil, cefprozil, cefatrizine

— Ampicillin ↔ cephalexin, cefaclor, cephradine, cephaloglycin

— Cefazolin has a unique side chain — usually safe across PCN allergy

— Ceftriaxone ↔ cefotaxime, cefepime (similar R1)

— Aztreonam ↔ ceftazidime (identical side chain) — avoid this pairing in true allergy

— Vancomycin → red man syndrome: non-IgE, slow infusion fixes

— Vancomycin → DRESS, linear IgA bullous dermatosis: stop

— Sulfonamides → SJS/TEN, AIN, hemolytic anemia in G6PD deficiency

— Cefaclor → serum sickness–like in children

— Allopurinol + HLA-B*58:01 → SJS/TEN

— Carbamazepine + HLA-B*15:02 → SJS/TEN (Asians)

— Abacavir + HLA-B*57:01 → hypersensitivity

— Amoxicillin + EBV → benign morbilliform rash (not true allergy)

— Aztreonam (avoid only with ceftazidime allergy)

— Cefazolin (unique side chain)

— Fluoroquinolones, macrolides, doxycycline, clindamycin, vancomycin, linezolid, daptomycin — structurally unrelated

— Syphilis in pregnancy

— Neurosyphilis

— Listeria meningitis (ampicillin)

— Enterococcal endocarditis (ampicillin)

— Group A strep with severe invasive disease (penicillin + clindamycin)

— Skin test reagents: PrePen (PPL) + Pen G

— Wheal increase ≥3 mm = positive

— Observation post-challenge: 60 min minimum

— Epinephrine dose: 0.3–0.5 mg IM lateral thigh, 1:1000

Epidemiology bullets:

Side-chain cross-reactivity pairs (R1 shared):

Reactions to know cold:

Drugs to know are SAFE in PCN allergy (most cases):

First-line therapy that requires penicillin (no good substitute):

Procedural anchors:

Board pearl: If asked the "single most important step" after a successful challenge, the answer is update the EHR allergy module, not "give the antibiotic."

Board Question Stem Patterns

— Adult with "PCN allergy" since age 5 (rash on amoxicillin during otitis, no anaphylaxis, no return visit), now needs cefazolin for hip arthroplasty.

— Answer: Proceed with cefazolin (or perform direct oral amoxicillin challenge in preop clinic). Do NOT substitute vancomycin.

— G2P1 at 24 weeks, RPR positive, FTA-ABS confirmed, history of penicillin anaphylaxis requiring epinephrine.

— Answer: Penicillin desensitization in monitored setting, then treat with benzathine penicillin G. Doxycycline contraindicated in pregnancy. Erythromycin/azithromycin inadequate for fetus.

— Patient with MSSA bacteremia receiving vancomycin due to "PCN allergy" labeled decades ago, vague history.

— Answer: Allergy de-labeling pathway / skin test / oral challenge → switch to cefazolin or nafcillin (lower mortality, faster clearance).

— Flushing and pruritus during first vancomycin infusion.

— Answer: Slow infusion, premedicate with diphenhydramine. Continue vancomycin. Do NOT label allergy. Do NOT switch to daptomycin/linezolid.

— Patient with prior SJS to sulfa now needs antibiotic; or DRESS to vancomycin.

— Answer: Strict avoidance of the implicated class; do NOT skin test, do NOT desensitize.

— Teen on amoxicillin for presumed strep develops diffuse maculopapular rash on day 5; monospot positive.

— Answer: Viral exanthem in setting of EBV — not a true PCN allergy; do not label.

— Patient with "PCN allergy — hives 30 years ago" presenting for elective cardiac surgery.

— Answer: Preoperative skin testing → oral challenge; use cefazolin if cleared. Vancomycin substitution increases SSI.

— Patient successfully de-labeled 1 year ago, now admitted to a different hospital with old label re-entered.

— Answer: Verify and remove label; this is a transitions-of-care/patient safety stem.

Stem pattern 1 — The mislabeled childhood reaction:

Stem pattern 2 — The pregnant syphilis patient:

Stem pattern 3 — MSSA bacteremia on vancomycin:

Stem pattern 4 — Vancomycin "red man":

Stem pattern 5 — SCAR history:

Stem pattern 6 — Mononucleosis rash:

Stem pattern 7 — Preoperative consult:

Stem pattern 8 — EHR reconciliation:

Step 3 management: Recognize that the "correct next step" is almost always clarify or de-label, not "switch to clindamycin/vancomycin/fluoroquinolone."

Board pearl: When the stem says "anaphylaxis requiring epinephrine to penicillin 1 year ago" and pregnant syphilis is the diagnosis → desensitization is the answer.

One-Line Recap

— PEN-FAST 0–1 → direct oral amoxicillin challenge

— Moderate risk → skin test then challenge

— High-risk IgE + essential drug → desensitize

— SCAR/organ-specific → strict class avoidance, no testing ever

— Cefazolin has a unique side chain → safe in nearly all PCN-allergic patients

— Aztreonam safe except with ceftazidime allergy

— Carbapenems <1% cross-reactivity

— Vancomycin "red man" is not an allergy — slow the infusion

— Syphilis in pregnancy, neurosyphilis, listeria, enterococcal endocarditis, MSSA bacteremia all do worse on non-beta-lactam alternatives

— Cefazolin for surgical prophylaxis halves SSI vs. vancomycin

— Update EHR allergy module (structured field), not just the note

— Provide patient wallet card

— Communicate to PCP, pharmacy, future surgical/OB teams

— Reconcile allergy list at every transition of care

The bottom line: Most "penicillin allergy" labels are wrong, cause measurable harm, and should be actively investigated through a structured pathway of history → PEN-FAST risk stratification → direct oral amoxicillin challenge (low risk) or skin testing ± challenge (moderate risk) or desensitization (high risk with essential indication), with absolute avoidance reserved only for SCARs and organ-specific reactions.

Four high-yield recap bullets:

Risk-stratify first:

Know the safe alternatives and the side-chain rules:

Never substitute inferior therapy when penicillin is the standard:

Document or it didn't happen:

Step 3 management: Treat antibiotic allergy de-labeling as an ambulatory quality intervention with the same systemic rigor as medication reconciliation — it is one of the highest-yield, lowest-cost, most underused patient safety actions available to internists.

Board pearl: When in doubt on Step 3, "de-label and use the beta-lactam" is almost always the better answer than "switch to vancomycin/clindamycin/fluoroquinolone."